The Rise Fund, a venture capital firm, led the $105m investment in RefleXion, a radiotherapy provider, with participation from Ally Bridge, Pfizer Ventures, Johnson & Johnson, Venrock, Catalio and Hillenbrand. “Closing an equity round of this size strongly affirms the conviction of our new and existing investors in fueling innovation for breakthrough treatment options, like SCINTIX therapy, in the battle against cancer. TPG’s support has been foundational in our journey, and we are gratified that they are leading a significant investment in RefleXion," Todd Powell, RefleXion President and CEO.